- Home
- SOR vs MNPR Comparison
SOR vs MNPR Comparison
Compare SOR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOR | MNPR |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.5M | 421.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SOR | MNPR |
|---|---|---|
| Price | $48.69 | $55.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $101.42 |
| AVG Volume (30 Days) | 16.2K | ★ 307.8K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 7.24% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 6.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.41 | $26.06 |
| 52 Week High | $42.75 | $105.00 |
Technical Indicators
Market Signals| Indicator | SOR | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 35.41 |
| Support Level | $47.89 | $55.00 |
| Resistance Level | $50.00 | $61.30 |
| Average True Range (ATR) | 0.89 | 4.67 |
| MACD | -0.03 | -0.66 |
| Stochastic Oscillator | 48.63 | 3.14 |
Price Performance
Historical ComparisonAbout SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.